That's likely to be a move to appease U.S. regulators, because, after the completion of the transaction, Medtronic will have its principal executive offices in Ireland. Acquiring the Irish company will undeniably have tax benefits for the resulting company, since Ireland has a much lower corporate tax rate than the U.S. and Medtronic will be able to run some of its profit through the country instead.
The Wall Street Journal, which initially broke the story, noted that Covidien had a 14.7% effective tax rate in 2012 that rose to 21.1% last year, due to unsettled matters with former parent company Tyco. Medtronic had an 18.4% tax rate in 2013.
Currently, Covidien is headquartered in Ireland, while Medtronic is based in Minneapolis, MN, where it employs more than 8,000 individuals. Medtronic will continue to have its operational headquarters in Minneapolis once the deal closes, which is likely to happen in the fourth quarter of 2014 or early 2015.
The move will further diversify Medtronic by adding its new major device and imaging industries. The combined companies will have 87,000 employees in more than 150 countries.
Based on the prior fiscal year revenues, the combined companies had $27.2 billion in revenue. Medtronic noted that of these combined revenues, $13 billion came from outside the U.S. and $3.7 billion as specifically from developing markets.
In its most recent quarter, Medtronic reported $4.6 billion in revenues. Of this, $2.4 billion (52%) came from its Cardiac and Vascular Group, which includes its cardiac rhythm disease management, coronary, structural heart and endovascular businesses; $1.7 billion (38%) from its Restorative Therapy Group, which consist of the spine, neuromodulation and surgical techniques business; and the remaining $460 million (10%) came from the Diabetes Group, which markets insulin pumps and glucose sensors.
For its part, in the most recent quarter Covidien had $2.6 billion in revenues from surgical solutions ($1.2 billion or 47%), respiratory and patient care ($976 million or 38%), and vascular therapies ($409 million or 16%).
The deal values Covidien at $93.22 per share based on Medtronic's most recent close of $60.70. The deal price is a 33% premium to Covidien's June 13 close. Per share, Covidien shareholders will receive $35.19 in cash and 0.956 of an ordinary Medtronic share. Covidien shareholders will end up owning about 30% of the subsequent company.
The transaction is expected to be accretive to Medtronic cash earnings in fiscal 2016 and significantly accretive thereafter. The joining of these companies is expected to result in at least $850 million in annual pre-tax cost synergies by the end of fiscal 2018. This will come from global back-office, manufacturing and supply-chain cuts as well as eliminating the dual costs of being a public company.
Bank of America Merrill Lynch committed financing for the transaction, but further details have yet to be disclosed. Medtronic had $14.2 billion in cash on April 25, with $4.6 billion of free cash flow in the last fiscal year.
The boards of directors from both companies have approved the deal; however it will also need to be approved by shareholders of both companies. The transaction will also have to clear regulators in the U.S., EU, China and other countries.
CANDIDATES WHO WANT TO BREAK INTO MEDICAL SALES:
RMSR® Medical Sales Certification offered by the National Association of Medical Sales Representatives is designed for entry level medical device sales reps. The course covers a wide array of topics pertaining to industry knowledge that candidates need to acquire before applying to medical sales positions.
The course and training helps to develop the industry skills, maximizing the candidates’ potential and goals, as well as making them feel valued and stimulated in their role when communicating with members of the medical community. By an applicant acquiring medical sales training and a RMSR Certification, it puts him/her in a position of strength and qualifies them for medical sales jobs. Medical knowledge is key in this industry and when communicating with doctors, surgeons, and nurses etc. It is extremely important for representatives to use key terminology pertaining to the medical product he/she will be promoting. The only way to succeed in this industry is to garner actual sales. Doctors and Surgeons will not acknowledge a Sales Rep who is not proficient in essential medical terminology, knowledgeable of medical devices/equipment and the anatomy. For those lacking a solid sales background the RMSR course covers knowledge of medical selling techniques and regulation such as Effective Territory Management, Effective Networking, Medical Sales Ethical & Regulatory Guidelines and more.
The National Association of Medical Sales Representative™
For more information on the NAMSR or the RMSR certification visit www.medicalsalescareer.com or call 800-313-9198